Table 3. Agreement between the final predicted responses and the pathologically determined responses.
| Final predicted response | Pathological responsea |
|||
| CR | PR | SD | PD | |
| Measured by CE | ||||
| CR | 7 | 7 | 0 | 0 |
| PR | 5 | 13 | 3 | 0 |
| SD | 0 | 4 | 0 | 0 |
| PD | 0 | 0 | 1 | 0 |
| Measured by MG | ||||
| CR | 5 | 0 | 0 | 0 |
| PR | 5 | 19 | 0 | 0 |
| SD | 2 | 6 | 3 | 0 |
| PD | 0 | 0 | 0 | 0 |
| Measured by US | ||||
| CR | 2 | 0 | 0 | 0 |
| PR | 8 | 18 | 1 | 0 |
| SD | 2 | 3 | 5 | 0 |
| PD | 0 | 0 | 0 | 1 |
| Measured by MRI | ||||
| CR | 9 | 1 | 0 | 0 |
| PR | 3 | 20 | 0 | 0 |
| SD | 0 | 2 | 5 | 0 |
| PD | 0 | 0 | 0 | 0 |
CE, clinical examination; CR, complete response; MG, mammography; PD, progressive disease; PR, partial response; SD, stable disease; US, sonography.
aPathological response was evaluated on the basis of the clinical examination or imaging findings at baseline, which differed according to the method used to predict residual tumour size. Hence, the number of patients in each of the pathological response categories (PR, SD and PD) is not the same for each prediction method.